Theme watch · maturing
Precision biotech stocks to watch · October 2026.
As of 11 October 2026
Kodiak Sciences' DAYBREAK win in wet AMD looks largely priced in, with the shares near the consensus target, deeply overbought and a launch still…
Iovance Biotherapeutics' raised FY2026 revenue guidance of $410–420 million, set two days before Q3 closed, still carries the case after a 229.5%…
Moderna's shares price in a strong Phase 3 melanoma result for its Merck-partnered cancer vaccine intismeran autogene. The 24 October 2026 ESMO…
Schrödinger's shares still trade well above the $20.80 consensus target after falling 11.3% to $28.90 on 6 October 2026, because software revenue…
ImmunityBio's bladder-cancer drug Anktiva grew Q2 2026 net product revenue 92% year over year to $50.7 million, which keeps supporting the shares…
Recursion Pharmaceuticals' early-October short-covering spike has faded, leaving the shares priced on pipeline hope while revenue shrinks; the…
"3-mo price move" is the stock's market price change, not a FrontierPicks return. The "3-mo price move" column is one of the three inputs to that score, weighted 20% — not the ranking itself, so rows do not descend in it. A dash means the name did not place in this week’s top-50 momentum scan, so it has no published 3-month figure.
How this page is built
These are the names FrontierPicks covers in the precision biotech stocks theme, each with a dated research dossier. Names on the momentum board rank first by a composite momentum score — 1-month price trend 50%, 3-month trend 20% and acceleration 30% — computed arithmetically from daily closing prices, through the last completed session, then the rest by conviction. The research decides which stocks belong to each theme; this one currently reads as maturing.
Questions
- What precision biotech stocks does FrontierPicks cover?
- As of 11 October 2026, the precision biotech stocks FrontierPicks tracks are led by KOD, IOVA, MRNA, SDGR, each with a dated research dossier. Names on the momentum board rank first by composite momentum score, then the rest by conviction.
- Is the precision biotech stocks theme accelerating or slowing?
- FrontierPicks reads this theme as maturing as of 11 October 2026. Clinical-stage and platform biotech names extended their rally after an NIH cancer-vaccine initiative was reported on Oct. 9, the same day Moderna (MRNA) hit a new 52-week high, and Kodiak Sciences (KOD) is up 179% over one month. The story is maturing: analysts are raising targets without upgrading ratings, with Baird lifting its Iovance (IOVA) target to $11 on Oct. 8 while staying at Neutral, and Schrödinger (SDGR) and Recursion (RXRX) are rising without company news. ImmunityBio (IBRX) was among the big gainers on Oct. 9.
- How does FrontierPicks rank precision biotech stocks?
- Every name links to its dated research dossier. Names on the momentum board rank first by composite momentum score, then the rest by conviction. The full method is on the methodology page.
Related
As of 11 October 2026